Braj News Magazine

(Albany) DelveInsight’s “Major Depressive Disorder Pipeline Insight 2023” report offers extensive knowledge on more than 75+ companies and 75+ pipeline drugs within the landscape of Major Depressive Disorder research. The Major Depressive Disorder Pipeline report provides detailed profiles of the Major Depressive Disorder pipeline drugs, encompassing both Major Depressive Disorder clinical trials and nonclinical stage products. Additionally, it assesses the therapeutics based on product type, stage, route of administration, and molecule type. Furthermore, the report sheds light on inactive pipeline products in this field.

In the Major Depressive Disorder Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Major Depressive Disorder clinical trials studies, Major Depressive Disorder NDA approvals (if any), and product development activities comprising the technology, Major Depressive Disorder collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

To explore more information on the latest breakthroughs in the Major Depressive Disorder Pipeline treatment landscape of the report, click here @ Major Depressive Disorder Pipeline Outlook

Key Takeaways from the Major Depressive Disorder Pipeline Report

• DelveInsight’s Major Depressive Disorder Pipeline analysis depicts a robust space with 75+ active players working to develop 75+ pipeline treatment therapies.
• The leading Major Depressive Disorder Companies are working in the market include GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals, and others.
• Promising Major Depressive Disorder Pipeline Therapies in the various stages of development include AXS-05, LY-03005, MIN-202, SAGE-217, REL-1017, CAPLYTA, PRAX 114, GH001, NBI-1065845, PH 10A, XW 10508 RP-5063, Zelquistinel, Apimostinel, SP-624, SLS-002, CTC-501 CLE-100, AV 101, OPC-64005, PDC 1421, NBI-1065845, MM-120, Zuranolone, AL001, SPL026, CTC-413, CYB003, GH001 and others.
• REL-1017, an NCE and novel NMDAR channel blocker with a preference for hyperactive channels associated with MDD. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for REL-1017 as an adjunctive treatment of MDD. REL-1017, has entered its Phase 3 registration program as an adjunctive treatment for MDD.
• Seltorexant is an innovative selective orexin 2 receptor antagonist under development for the treatment of insomnia and related mood disorders. Insomnia is the repeated difficulty with sleep initiation, maintenance or quality that occurs despite adequate time and opportunity for sleep, resulting in daytime impairment. The clinical trials are being carried out for the treatment of major depressive disorder in phase III stage of development.
• SP-624 is being studied in phase II stage of development for the treatment of major depressive disorder in comparison with placebo by Sirtsei Pharmaceuticals, Inc.
• SPL026 (DMT), is a naturally occurring psychedelic tryptamine found in plants and in the brain of mammals. Scientific evidence suggests DMT offers the potential for rapid-acting and long-lasting antidepressant effects. DMT is differentiated by its short psychedelic experience (< 30mins), which allows for short treatment sessions and offers the potential for convenient supervised treatments within patient clinics. Small Pharma is advancing a pipeline of DMT-based therapies and is leading the world’s first DMT clinical trial for depression, in collaboration with Imperial College London.
• PDC-1421 (BLI-1005) is a Norepinephrine plasma membrane transport protein inhibitor being developed by BioLite Inc, for the treatment of major depressive disorder. The drug is currently in phase II stage of development.

Major Depressive Disorder Overview

Major Depressive Disorder (MDD), also referred to as clinical depression, is a significant medical condition that can affect many areas of your life. It impacts mood and behavior as well as various physical functions, such as appetite and sleep. The exact cause of MDD isn’t known. However, there are several factors that can increase the risk of developing the condition.

For further information, refer to the detailed Major Depressive Disorder Unmet Needs, Major Depressive Disorder Market Drivers, and Major Depressive Disorder Market Barriers, click here for Major Depressive Disorder Ongoing Clinical Trial Analysis

Major Depressive Disorder Emerging Drugs Profile

• SAGE-217: Sage Therapeutics
• REL-1017: Relmada Therapeutics, Inc
• Seltorexant: Minerva Sciences
• SP-624: Sirtsei Pharmaceuticals, Inc.
• SPL026: Small Pharma
• PDC-1421: BioLite Inc

Major Depressive Disorder Pipeline Segmentation

There are approx. 75+ Major Depressive Disorder companies which are developing the therapies for Major Depressive Disorder. The Major Depressive Disorder companies which have their Major Depressive Disorder drug candidates in the most advanced stage, i.e. Preregistration include SAGE Therapeutics.

Request a sample and discover the recent advances in Major Depressive Disorder Ongoing Clinical Trial Analysis and Medications, click here @ Major Depressive Disorder Treatment Landscape

Major Depressive Disorder Pipeline Segmentation

• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Some of the Companies in the Major Depressive Disorder Therapeutics Market include-

GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals, and others.

Dive deep into rich insights for drugs for Major Depressive Disorder Pipeline, click here @ Major Depressive Disorder Unmet Needs and Analyst Views

Scope of the Major Depressive Disorder Pipeline Report

• Coverage- Global
• Major Depressive Disorder Companies- GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals, and others.
• Major Depressive Disorder Pipeline Therapies- AXS-05, LY-03005, MIN-202, SAGE-217, REL-1017, CAPLYTA, PRAX 114, GH001, NBI-1065845, PH 10A, XW 10508 RP-5063, Zelquistinel, Apimostinel, SP-624, SLS-002, CTC-501 CLE-100, AV 101, OPC-64005, PDC 1421, NBI-1065845, MM-120, Zuranolone, AL001, SPL026, CTC-413, CYB003, GH001 and others
• Major Depressive Disorder Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on Major Depressive Disorder Mergers and acquisitions, Major Depressive Disorder Licensing Activities @ Major Depressive Disorder Emerging Drugs, and Recent Trends

Table of Content

1. Introduction
2. Major Depressive Disorder Executive Summary
3. Major Depressive Disorder: Overview
4. Major Depressive Disorder Pipeline Therapeutics
5. Major Depressive Disorder Therapeutic Assessment
6. Major Depressive Disorder – DelveInsight’s Analytical Perspective
7. Late Stage Products (Preregistration)
8. SAGE-217: Sage Therapeutics
9. Drug profiles in the detailed report…..
10. Mid-Stage Products (Phase II)
11. SP-624: Sirtsei Pharmaceuticals, Inc.
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. SPL026: Small Pharma
15. Drug profiles in the detailed report…..
16. Preclinical Stage Products
17. Drug Name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Major Depressive Disorder Key Companies
21. Major Depressive Disorder Key Products
22. Major Depressive Disorder- Unmet Needs
23. Major Depressive Disorder- Market Drivers and Barriers
24. Major Depressive Disorder- Future Perspectives and Conclusion
25. Major Depressive Disorder Analyst Views
26. Major Depressive Disorder Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare focussed market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services